Dyne Therapeutics Inc. (DYN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Dyne Therapeutics: A Buy, With Caveats, On DMD Progress
Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launch in Q1 2027. DYN demonstrates best-in-class dystrophin expression in registrational trials, targeting a $3.5bn market for exon 51 skipping DMD patients. Robust pipeline includes z-basivarsen for DM1, with pivotal data expected Q1 2027 and potential accelerated approval/launch in 2028.
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dystrophy.
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission
Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD programs targeting significant unmet needs. DYN expects to file a BLA for z-rostudirsen in DMD exon 51 skipping patients in Q2 2026, with potential commercialization by Q1 2027. Top-line data from the phase 1/2 ACHIEVE REC study in DM1 is anticipated in Q1 2027, supporting future accelerated approval filings.
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case
Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating expenses in 2025. Encouraging long-term cardiopulmonary data from the DELIVER trial of z-rostudirsen (DYNE-251) strengthens the bull case for DMD therapy. Initiation of the pivotal Phase 3 HARMONIA trial for DYNE-101 in DM1 marks a critical regulatory and value inflection point.
Dyne Therapeutics: 2026 Catalysts Point To Further Upside
Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases with two lead clinical programs approaching pivotal milestones. DYNE-101 shows strong safety and functional improvement in DM1, with a potential BLA submission in Q3 2027 but faces competition and a lengthy timeline. DYNE-251's efficacy in DMD lags behind Avidity on a numerical basis, with a narrow therapeutic window and safety concerns at higher doses.
Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dyne Therapeutics: Why The $350M Public Offering Was Critical
Dyne Therapeutics, Inc. faces a pivotal 2026 with key milestones for DYNE-101 and DYNE-251, supported by a well-timed $350M equity raise. The recent offering extends DYN's cash runway by roughly one year, providing financial flexibility for late-stage trials and regulatory submissions. DYNE-101 and DYNE-251 both show promising safety and efficacy data, with potential accelerated FDA submissions targeted for late 2026.
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026
Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects key catalysts: DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late 2026. The pipeline includes zeleciment rostudirsen for DMD exon 51 skipping patients, with registrational cohort data expected in late 2025 and a potential BLA in early 2026.
Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?
The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
